MARGINAL ZONE LYMPHOMA

This study compares standard radiation (24 Gy) to a very low dose (4 Gy) for people with follicular or marginal zone lymphoma. The goal is to see if the low dose works just as well but causes fewer side effects. About 375 participants will be enrolled, and the study is currently …

This study tests a new vaccine (EO2463) designed to train the immune system to attack lymphoma cells. It is for people with follicular or marginal zone lymphoma, either newly diagnosed or after prior treatment. The vaccine is given alone or with standard drugs lenalidomide and ri…

This early-phase study tests a new type of CAR T cell therapy that targets two proteins (CD79b and CD19) on lymphoma cells. It is for people with non-Hodgkin lymphoma that has come back or not responded to standard treatments. The main goals are to check safety and find the right…

This study tests a new treatment called CTX112 for people with B-cell blood cancers (like lymphoma or leukemia) that have come back or not responded to standard therapy. CTX112 uses CRISPR gene-editing to create donor T-cells that target and kill cancer cells. The trial involves …

This study is for people with certain blood cancers (like CLL or lymphoma) who are starting a type of drug called a BTK inhibitor. These drugs can raise blood pressure and increase the risk of heart problems. The study will test if carefully managing high blood pressure can lower…

This early-phase study tests a new treatment called SynKIR-310 for adults with B-cell non-Hodgkin lymphoma that has come back or not responded to at least two prior therapies. The treatment uses a patient's own immune cells, modified to recognize and attack cancer cells. The main…

This early-stage study tests a new gene therapy called VNX-101 for people with certain blood cancers (like leukemia and lymphoma) that have returned or not improved with standard treatments. The therapy uses a harmless virus to deliver a gene that helps the immune system attack c…

This study tests whether combining pirtobrutinib (a targeted pill) with rituximab (an antibody infusion) can shrink or eliminate tumors in people newly diagnosed with marginal zone lymphoma. About 23 adults who need treatment but haven't had prior systemic therapy will receive th…

This early-phase trial tests an oral drug called AS-1763 in adults with certain blood cancers (like CLL or lymphoma) that have not responded to at least two prior treatments. The main goals are to find the safest dose and see if the drug can shrink tumors. Around 120 participants…

This study tests an investigational drug called epcoritamab in 25 adults newly diagnosed with marginal zone lymphoma, a slow-growing blood cancer. The goal is to see if the drug can shrink or eliminate tumors. Participants will receive the drug for several cycles, and doctors wil…

This study is for people with B-cell blood cancers like lymphoma and leukemia. It tests a new drug, BGB-16673, that breaks down a protein helping cancer grow. The goal is to find the right dose and see if it is safe and shrinks tumors. About 146 people in China will take part.

This study tests whether a combination of two drugs, mosunetuzumab and lenalidomide, works better than standard treatments for people with marginal zone lymphoma that has come back or stopped responding to therapy. About 260 adults who have had 1 to 3 prior treatments will be ran…

This study tests a drug called pemigatinib in adults with certain types of B-cell non-Hodgkin lymphoma that have come back or not responded to at least two prior treatments. The goal is to see if the drug can shrink tumors or stop the cancer from growing. About 27 participants wi…

This early-phase study is testing an experimental oral drug called LP-168 in about 60 people with certain blood cancers (like CLL, lymphoma, and Waldenstrom macroglobulinemia) that have returned or not responded to prior therapies. The main goals are to find the safest dose and u…

This study tests a combination of two drugs, acalabrutinib and obinutuzumab, in people with untreated, slow-growing lymphomas like follicular lymphoma. The goal is to see if the combo can shrink tumors and control the disease. About 49 adults will take part, and researchers will …

This study is for people with certain types of B-cell or Hodgkin lymphoma. Participants first get a stem cell transplant using their own cells, then receive a targeted drug called polatuzumab vedotin every 3 weeks for up to 8 doses. The goal is to see if this approach is safe and…

This study tests an experimental drug called BGB-16673 in people with several types of B-cell cancers (like lymphoma and leukemia) that have come back or not responded to other treatments. The drug works by breaking down a protein (BTK) that helps these cancer cells grow. The tri…

This study tests a two-drug combination (mosunetuzumab and lenalidomide) as the first treatment for adults with follicular or marginal zone lymphoma. Participants start with mosunetuzumab alone, then add lenalidomide if the cancer only partially responds. The goal is to see how m…

This study is testing a combination of two drugs, zanubrutinib and rituximab, as a first treatment for people with marginal zone lymphoma, a slow-growing blood cancer. About 30 adults will take part to see how well the combo shrinks tumors and keeps the disease from progressing. …

This study tests a drug called orelabrutinib in 30 people with untreated marginal zone lymphoma, a slow-growing blood cancer. The goal is to see how well the drug shrinks tumors and to check for side effects. Participants take the drug by mouth and are followed for response and s…

This study is testing whether a combination of two drugs, rituximab and zanubrutinib, is safe and works well for people with untreated follicular lymphoma or marginal zone lymphoma. About 43 adults will take both drugs and be monitored for response and side effects. The goal is t…

This early-phase study tests a new treatment for adults with B-cell blood cancers (like lymphoma) that have not responded to prior therapies. Participants receive a special type of immune cell (CAR T-cells) along with a targeted drug called pirtobrutinib, which is given before an…

This study tests whether combining two drugs, rituximab and venetoclax, can shrink or eliminate tumors in people with untreated marginal zone lymphoma. About 33 participants will receive the treatment to see how many achieve complete remission. The goal is to find a more effectiv…

This study tests a new type of CAR-T cell therapy that targets two proteins (CD19 and CD20) on cancer cells, aiming to treat adults with B-cell blood cancers like lymphoma and leukemia that have not responded to other treatments. The therapy uses the patient's own immune cells, w…

This study tests a drug called loncastuximab tesirine in 50 adults with marginal zone lymphoma that has returned or not responded to prior therapy. The drug is designed to deliver a toxin directly to cancer cells. Researchers will measure how many participants achieve complete re…

This study tests a new drug, orelabrutinib, combined with chemotherapy for people newly diagnosed with marginal zone lymphoma, a rare blood cancer. About 69 participants will receive the treatment to see if it improves tumor shrinkage and helps control the disease long-term. The …

This study compares two drug combinations for people with follicular or marginal zone lymphoma that has come back or not responded to prior treatment. About 780 participants will receive either zanubrutinib plus an anti-CD20 antibody or lenalidomide plus rituximab. The goal is to…

This study tests a combination of three drugs—epcoritamab, zanubrutinib, and rituximab—in people with follicular lymphoma or marginal zone lymphoma that has come back or not responded to prior treatment. The goal is to see how well the combo works at shrinking tumors and to check…

This study is testing whether an artificial intelligence tool can help match cancer patients to clinical trials they might be eligible for. Researchers will enroll up to 50,000 people with various types of cancer and use the AI to suggest trials. The goal is to see if this approa…

This study will follow 2500 people newly diagnosed with marginal zone B-cell lymphoma to learn more about the disease, how it is treated, and what happens over time. Participants will provide blood and tissue samples and be followed for years. The goal is to better understand the…

This study is observing adults with Waldenström's macroglobulinemia, chronic lymphocytic leukemia, marginal zone lymphoma, or follicular lymphoma who are taking the drug zanubrutinib. Researchers want to see how often patients need hospital care and how their quality of life chan…